Cardiovascular Disease Doctors in Garden City, NY Accepting Medicare

26 Cardiovascular Disease doctors found. Showing 21 - 26

Greg Kaufman, M.D. Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 901 Stewart Ave, Suite 220, Garden City, NY 11530 Phone: 516-222-0404    Fax: 516-222-2268

Jonathan Nichol Jordan, Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 975 Stewart Ave, Garden City, NY 11530 Phone: 516-222-8640    Fax: 516-745-5479

Dr. Paul E Harnick, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 975 Stewart Ave, Garden City, NY 11530 Phone: 516-222-6490    Fax: 516-745-5476

Dr. Jeffrey A Leonardis, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 975 Stewart Ave, Garden City, NY 11530 Phone: 516-222-8687    Fax: 516-745-5476

Dr. Richard Bryan Jacaruso, D.O. Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1401 Franklin Avenue, Garden City, NY 11530 Phone: 516-877-2626    Fax: 516-877-0945

Gregory Macina, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 975 Stewart Ave, Garden City, NY 11530 Phone: 516-222-8625    Fax: 516-745-5476

News Archive

Non-invasive fetal oxygen monitor could improve outcomes in difficult deliveries

A device to directly measure blood oxygen saturation in a fetus during labor has been developed by researchers at the University of California, Davis.

IQWiG finds minor added benefit of dulaglutide in combination with short-acting insulin for type 2 diabetes

Since 2014 dulaglutide has been approved alone or in combination with other drugs for the treatment of adults with type 2 diabetes. The German Institute for Quality and Efficiency in Health Care examined in a dossier assessment whether this new drug offers an added benefit over the appropriate comparator therapies.

Biogen begins ISIS-SOD1 Rx Phase 1/2 clinical study in patients with amyotrophic lateral sclerosis

Isis Pharmaceuticals, Inc. today announced that its partner, Biogen, has initiated a Phase 1/2 clinical study of ISIS-SOD1 Rx (BIIB067) in patients with amyotrophic lateral sclerosis (ALS).

New way to generate genetically altered influenza virus

In the event of an influenza pandemic, the world's vaccine manufacturers will be in a race against time to forestall calamity.

Read more Medical News

› Verified 5 days ago

• 1
• 2(current)